Picture supply: Getty Pictures
There are many market-beating UK shares for traders to find in 2025. And it appears the analyst group at Barclays Capital has its eyes set on three British companies specifically.
Every operates in its personal respective business, together with power, prescription drugs, and mining. And after a fast look at institutional forecasts, all three appear to be sitting on substantial upward potential. So, ought to traders be contemplating these companies for their very own portfolios?
Barclay’s highest-conviction concepts
Amongst all of the British shares, Barclays Capital has beneficial, the three which have stood out are Shell (LSE:SHEL), AstraZeneca (LSE:AZN), and Anglo American (LSE:AAL).
Let’s begin with the oil & gasoline big. Barclay’s analyst Lydia Rainforth reiterated her robust conviction in April, citing the group’s spectacular shareholder rewards scheme. The agency is anticipated to spice up dividends by 10% to twenty% as early as 2026, with upstream manufacturing probably hitting three million barrels of oil equivalents by 2029.
Regardless of some scepticism surrounding Shell’s potential to spice up product volumes, Barclays has a 3,800p value goal for the Shell share value – roughly 53% greater than present costs.
Shifting over to the world of prescription drugs, AstraZeneca is one other enterprise receiving some love from Barclays analysts. Emily Discipline issued a Purchase score with a 14,000p value goal slightly below a month in the past. It adopted a sequence of regulatory approvals and additional constructive medical trial ends in the primary quarter of 2025. And with administration reiterating its $80bn income goal by 2030, Discipline’s conviction for a 30% soar actually makes lots of sense.
Lastly, now we have Anglo American. Regardless of many different analysts like Berenberg Financial institution and RBC Capital Markets not too long ago issuing Promote studies, Barclays has retained its conviction behind this enterprise. It appears its analysts had been impressed with the progress Anglo has been making in its cost-cutting efforts, in addition to the copper and iron ore segments. And whereas the value goal was lowered from 3,000p to 2,650p, that also represents a possible 24% achieve over the following 12 months.
Are these good inventory picks?
Wanting once more at Shell, the agency has and can at all times proceed to be delicate to grease costs whereas it stays a fossil gas power enterprise. Even with a powerful conviction within the enterprise, Barclays is projecting that oil costs might endure following the OPEC+ shift in manufacturing technique, in addition to anticipated frontloading courtesy of commerce tariffs.
Tariffs aren’t anticipated to be as massive a difficulty for AstraZeneca. Nevertheless, the biotech big is dealing with its personal set of complications in China, considered one of its core development markets. The agency is dealing with multi-million-dollar fines regarding suspected unpaid import taxes on its medication. Whereas that’s not prone to be catastrophic, regulatory disruptions in China might set off volatility, particularly for a inventory buying and selling at a price-to-earnings ratio of virtually 30.
Anglo American can also be tackling its justifiable share of complications with its ongoing restructuring. The group’s latest asset gross sales and cost-cutting measures are anticipated to ship long-term worth. However within the quick time period, it’s creating uncertainty, which can solely be exacerbated by operational challenges in Peru.
Digging by every of the funding theses, the analysts have made compelling arguments for why every enterprise is amongst their favorite picks proper now. Nevertheless, none are significantly tempting for my portfolio, particularly since I believe there are much more compelling funding alternatives amongst different UK shares.
